BetaGlue® Therapeutics Announces Publication in Nuclear Medicine and Biology of the First In Vivo Preclinical Evaluation of YntraDose® in Lung Tissue

Milan, August 14th 2026 – BetaGlue® Therapeutics S.p.A. (“BetaGlue”), a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose®, announced today the publication in Nuclear Medicine and Biology of a peer-reviewed article entitled: “In vivo preclinical evaluation of YntraDose™ in pig’s lung: A pilot study of a ⁹⁰Y-microsphere device implantation.”

The study, carried out at Fondazione Policlinico Universitario “A. Gemelli” IRCCS in Rome, is the first in vivo evaluation of YntraDose administration into lung tissue. Seven healthy Landrace pigs received ultrasound-guided percutaneous injections of YntraDose into two lung lobes (5 ml and 10 ml, 150–185 MBq) and were followed over 21 days with PET/CT imaging, dosimetry, necropsy and histological analysis. The findings were:

1. YntraDose could be injected and polymerised within lung tissue, forming a localised implant visible both on imaging and at necropsy;
2. No activity above the limit of detection was measured outside the injected lung — in whole blood or in the contralateral lung, heart, kidneys, liver, intestine and bladder — indicating no detectable systemic spread of ⁹⁰Y;
3. Estimated absorbed doses ranged from 342.5 to 786.0 Gy, with necrosis localised around the deposition site and extending approximately 1 to 1.5 cm from its centre;
4. A marked inflammatory response was observed, with IL-1β, IL-6 and IL-8 positive cells distributed throughout the tissue.

The authors conclude that YntraDose can be successfully injected and polymerised in lung tissue, even at high radioactivity levels, and that these results support further preclinical studies using optimised, clinically relevant ⁹⁰Y activities to evaluate the potential of YntraDose for localised lung tumour ablation.

This is a preclinical study conducted in healthy animals. YntraDose® is an investigational product and is not approved for use in lung indications.

The article is published open access and is available at https://doi.org/10.1016/j.nucmedbio.2026.109658.

This pilot study is an important first step for our lung programme. It shows that YntraDose can be delivered and polymerised within lung tissue under image guidance, and that the radioactive payload remained confined to the injection site, with no activity detectable in any other organ. The inflammatory response we observed will directly inform the design of the next studies, in which we will work with optimised, clinically relevant activities.

Dr Gianluca De Danieli

Clinical Development Head, BetaGlue Therapeutics

Reference: Lanni V, Nocera A, Vita ML, Lupoi L, Caristo ME, Straino S, Cianfarani F, Bellavia G, Capotosti A, Indovina L, Moretti R, De Danieli G, Bubba Bello P, Bisaccioni G, Calcagni ML, Scotognella T. In vivo preclinical evaluation of YntraDose™ in pig’s lung: A pilot study of a ⁹⁰Y-microsphere device implantation. Nuclear Medicine and Biology 2026;158–159:109658.